Allergan plc is an Irish–tax registered pharmaceutical company that acquires, develops, and markets branded drugs, and in 2017 generated 80% net sales from the U.S. healthcare system. Allergan plc was formed in February 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name. Actavis was a 2013 U.S. corporate tax inversion who moved to Ireland to avoid U.S. taxes on their income, almost all of which came from the U.S. healthcare system. Actavis used the Irish low-tax corporate system to acquire large U.S. pharmaceutical firms (e.g. Forest Labs, Allergan Inc.), and redomicile them to Ireland. In 2016, the U.S. blocked Actavis from executing what would have been the largest corporate tax inversion in history with Pfizer.Using Ireland's low-tax regime, Allergan acquires, develops, reprices, and markets branded products in six therapeutic areas: aesthetics/dermatology/plastic surgery; neurosciences/CNS; eye care; women’s health and urology; GI and cystic fibrosis; and cardiovascular disease and infectious disease. The company's products include Botox (botulinum toxin), Namenda (memantine), Restasis (ciclosporin), Linzess (linaclotide), Bystolic (nebivolol), Juvederm (injectable filler), Latisse (bimatoprost), Lo Loestrin Fe, Estrace (estradiol), Teflaro (ceftaroline fosamil), Dalvance (dalbavancin, Ozurdex (dexamethasone), Optive, Natrelle, Viibryd (vilazodone), Liletta (levonorgestrel), Saphris (asenapine), Enablex (darifenacin), Actonel (risedronic acid), Androderm (testosterone), and Gelnique (oxybutynin).